Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Kepler Cheuvreux
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech Sartorius Stedim Biotech SA Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech 03-Jul-2026 / 10:03 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ERG upgraded to “buy” by Kepler Cheuvreux on supportive EU policy; shares up 7%
Investing.com -- Kepler Cheuvreux upgraded Italian renewable energy company ERG to “buy” from “hold” rating and raised its target price to €27 from €24, citing a more supportive policy environment for renewable energy players across Europe, sending shares up over 7% on Friday.
ERG upgraded to “buy” by Kepler Cheuvreux on supportive EU policy; shares up 7%
Investing.com -- Kepler Cheuvreux upgraded Italian renewable energy company to “buy” from “hold” rating and raised its target price to €27 from €24, citing a more supportive policy environment for renewable energy players across Europe, sending shares up over 7% on Friday.
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech -2-
DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech Sartorius Stedim Biotech SA Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech 06-Jan-2026 / 10:23 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Legrand downgraded to “hold” by Kepler Cheuvreux; stock down
Investing.com -- Kepler Cheuvreux cut its recommendation on Legrand SA (EPA:LEGD) to "hold" from "buy," pointing to stretched valuations and expectations running ahead of company guidance, sending shares lower on Wednesday. The brokerage said Legrand’s shares have already priced in much of the positive outlook, particularly in its data center business, which is expected to remain a strong driver of growth.
Henri Sinet rejoint Kepler Cheuvreux en tant que Senior Credit Sales
Kepler Cheuvreux a le plaisir d’annoncer la nomination d’Henri Sinet en tant que Senior Credit Sales, basé à Paris. Henri bénéficie de 10 ans d’expérience en trading acquise chez CA CIB, CIC et Mizuho, où il s’est concentré dans un premier temps sur les financières, puis plus récemment sur les secteurs Investment Grade de l’automobile et de la pharmacie. Ce recrutement constitue une étape clé dans le plan ambitieux de Kepler Cheuvreux visant à renforcer sa franchise Fixed Income.
Umicore stock rating cut by Kepler Cheuvreux, target to EUR10.50
Umicore stock rating cut by Kepler Cheuvreux, target to EUR10.50 On Friday, Kepler Cheuvreux analysts adjusted their stance on Umicore SA (UMI:BB) (OTC: OTC:), downgrading the stock from "Buy" to "Hold" and slashing the price target significantly to EUR 10.50 from the previous EUR 18.00. The revision followed a reassessment of the company's performance and prospects, particularly focusing on its Battery Materials (BM) division.
Kepler Cheuvreux annonce la nomination de Mathieu Chabot en tant que Managing Director
Mathieu a rejoint Kepler Cheuvreux Corporate Finance en 2017 après 7 années en banque d’investissement chez Goldman Sachs. Il est diplômé de l'ESSEC. Depuis son arrivée, Mathieu a joué un rôle décisif dans la croissance de Kepler Cheuvreux Corporate Finance. Il a notamment mené le développement de l’activité de conseil en fusions-acquisitions pour les acteurs de l’immobilier, tout en renforçant l’expertise de l’équipe sur les sujets M&A et levées de fonds.
Affluent Medical announces coverage initiation of its stock by Gilbert Dupont - Société Générale Group.
DJ Affluent Medical announces coverage initiation of its stock by Gilbert Dupont - Société Générale Group.
Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.
DJ Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.
Affluent Medical: Half-year liquidity contract statement for Affluent Medical
DJ Affluent Medical: Half-year liquidity contract statement for Affluent Medical. Affluent Medical Affluent Medical: Half-year liquidity contract statement for Affluent Medical. 29-Jan-2024 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Affluent Medical: Half-year liquidity contract statement for Affluent Medical.
DJ Affluent Medical: Half-year liquidity contract statement for Affluent Medical. Affluent Medical Affluent Medical: Half-year liquidity contract statement for Affluent Medical. 29-Jan-2024 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Charwood Energy: Half-year liquidity contract statement for Charwood Energy
DJ Charwood Energy: Half-year liquidity contract statement for Charwood Energy Charwood Energy Charwood Energy: Half-year liquidity contract statement for Charwood Energy 05-Jan-2024 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Charwood Energy: Half-year liquidity contract -2-
DJ Charwood Energy: Half-year liquidity contract statement for CHARWOOD ENERGY Charwood Energy Charwood Energy: Half-year liquidity contract statement for CHARWOOD ENERGY 05-Jan-2024 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech Sartorius Stedim Biotech SA Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech 05-Jan-2024 / 09:49 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Affluent Medical announces coverage initiation of its stock by Portzamparc - Groupe BNP Paribas.
DJ Affluent Medical announces coverage initiation of its stock by Portzamparc - Groupe BNP Paribas. Affluent Medical Affluent Medical announces coverage initiation of its stock by Portzamparc - Groupe BNP Paribas. 27-Nov-2023 / 07:30 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Affluent Medical: Half-year liquidity contract statement.
DJ Affluent Medical: Half-year liquidity contract statement. Affluent Medical Affluent Medical: Half-year liquidity contract statement. 25-Jul-2023 / 17:40 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Charwood Energy: Half-year liquidity contract statement for Charwood Energy
DJ Charwood Energy: Half-year liquidity contract statement for CHARWOOD ENERGY Charwood Energy Charwood Energy: Half-year liquidity contract statement for CHARWOOD ENERGY 07-Jul-2023 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Charwood Energy: Half-year liquidity contract -2-
DJ Charwood Energy: Half-year liquidity contract statement for CHARWOOD ENERGY Charwood Energy Charwood Energy: Half-year liquidity contract statement for CHARWOOD ENERGY 07-Jul-2023 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Sartorius Stedim Biotech SA: Half-year liquidity -2-
DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech Sartorius Stedim Biotech SA Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech 05-Jul-2023 / 13:55 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
PSD Bank Rhein-Ruhr eG
BofA Securities and BNP Paribas Exane share first place as top research provider in the Developed Europe survey BofA Securities, HSBC and J.P. Morgan share top spot in Emerging EMEA and Investec is best broker for UK Small & Midcap NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Institutional Investor Research (II Research) surveys are the leading provider of market sentiment in the financial industry.
KLÉPIERRE TERMINATES ITS EXISTING LIQUIDITY AGREEMENT AND ENTERS INTO A NEW LIQUIDITY AGREEMENT
REGULATORY RELEASE KLÉPIERRE TERMINATES ITS EXISTING LIQUIDITY AGREEMENT AND ENTERS INTO A NEW LIQUIDITY AGREEMENT Paris, January 31, 2023 KLÉPIERRE TERMINATES ITS EXISTING LIQUIDITY AGREEMENT Klépierre SA (ISIN FR0000121964) announces that, as of January 31, 2023, it has terminated the liquidity agreement for its shares listed on Euronext Paris, entered into with Rothschild Martin Maurel on February 1, 2019.
MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux
MaaT Pharma (EURONEXT: MAAT - the 'Company'), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces the initiation of coverage of its stock by Kepler Cheuvreux. With a research report named 'The Microbiome revolution', Kepler Cheuvreux today initiates coverage of MaaT Pharma with a Buy recommendation.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
프랑스 리옹–(BUSINESS WIRE)–$MAAT– 규제 뉴스 : MaaT 제약(EURONEXT: MAAT - "회사"), 프랑스의 임상 단계 생명공학 기업이자 Microbiome Ecosystem Therapies 개발의 선구자TM (MET) 암 환자의 생존 결과 개선에 전념 오늘 Kepler Cheuvreux가 자사 주식에 대한 커버리지를 시작한다고 발표했습니다. 라는 연구 보고서와 함께 "마이크로바이옴 혁명", 케플러 슈브뢰오늘은 구매 권장 사항과 함께 MaaT Pharma의 범위를 시작합니다. 이 새로운 커버리지는 프랑스 및 국제 기관 투자자들 사이에서 MaaT Pharma의 점유율 가시성을 강화하고 중개 회사인 KBC Securities, Kempen 및 Portzamparc/Groupe BNP Paribas가 이미 수행한 커버리지에 추가됩니다.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, Faransa–(WIRE KASUWANCI)–$MAAT–Labaran Da Aka Kafa: MaAT Pharma(EURONEXT: MAAT - "Kamfanin"), Faransanci-matakin ilimin halittu na asibiti da kuma majagaba a cikin ci gaban Microbiome Ecosystem TherapiesTM (MET) sadaukar don inganta sakamakon rayuwa ga marasa lafiya da ciwon daji, today announces the initiation of coverage of its stock by Kepler Cheuvreux.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, Frankreich–(BUSINESS WIRE)–$MAAT–Regulatorische Nachrichten: MaaT-Pharma(EURONEXT: MAAT – das „Unternehmen“), ein französisches Biotech-Unternehmen im klinischen Stadium und ein Pionier in der Entwicklung von Mikrobiom-ÖkosystemtherapienTM (MET) zur Verbesserung der Überlebenschancen von Krebspatienten, gibt heute den Beginn der Coverage seiner Aktie durch Kepler Cheuvreux bekannt.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, Prancis–(Antara/BUSINESS WIRE)–$MAAT–Berita Peraturan: Farmasi Maat(EURONEXT: MAAT – “Perusahaan”), bioteknologi tahap klinis Prancis dan pelopor dalam pengembangan Terapi Ekosistem MicrobiomeTM (MET) didedikasikan untuk meningkatkan hasil kelangsungan hidup bagi pasien dengan kanker, today announces the initiation of coverage of its stock by Kepler Cheuvreux.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, Frankrike–(BUSINESS WIRE)–$MAAT–Reglerande nyheter: MaaT Pharma(EURONEXT: MAAT – "Företaget"), en fransk bioteknik på kliniskt stadium och en pionjär inom utvecklingen av mikrobiomekosystemterapierTM (MET) tillägnad att förbättra överlevnadsresultat för patienter med cancer, today announces the initiation of coverage of its stock by Kepler Cheuvreux. With a research report named “The Microbiome revolution”, Kepler Cheuvreuxtoday initiates coverage of MaaT Pharma with a Buy recommendation.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, Frankrike–(BUSINESS WIRE)–$MAAT–Regulerende nyheter: MaaT Pharma(EURONEXT: MAAT - "Selskapet"), en fransk bioteknologi på klinisk stadium og en pioner innen utvikling av mikrobiomeøkosystemterapierTM (MET) dedikert til å forbedre overlevelsesresultater for pasienter med kreft, kunngjør i dag at Kepler Cheuvreux har startet dekning av aksjen. Med en forskningsrapport kalt "Mikrobiom-revolusjonen", Kepler Cheuvreuxstarter i dag dekning av MaaT Pharma med en kjøpsanbefaling.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, Francija–(BUSINESS WIRE)–$MAAT–Pravilne novice: MaaT Pharma(EURONEXT: MAAT – »podjetje«), francoska biotehnologija na klinični stopnji in pionir v razvoju mikrobiomskih ekosistemskih terapijTM (MET), namenjeno izboljšanju rezultatov preživetja bolnikov z rakom, today announces the initiation of coverage of its stock by Kepler Cheuvreux. With a research report named “The Microbiome revolution”, Kepler Cheuvreuxtoday initiates coverage of MaaT Pharma with a Buy recommendation.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
ЛИОН, Франция–(БИЗНЕС-ПРОВОД)–$МААТ–Новости регулирования: Маат Фарма(EURONEXT: MAAT — «Компания»), французская биотехнологическая компания клинической стадии и пионер в разработке микробиомной экосистемной терапии.TM (MET), посвященный улучшению результатов выживаемости пациентов с раком, сегодня объявляет о начале покрытия своих акций компанией Kepler Cheuvreux.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, France–(BUSINESS WIRE)–$MAAT–Regulatory News: MaaT Pharma(EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces the initiation of coverage of its stock by Kepler Cheuvreux. With a research report named “The Microbiome revolution”, Kepler Cheuvreuxtoday initiates coverage of MaaT Pharma with a Buy recommendation.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, França–(BUSINESS WIRE)–$MAAT–Notícias regulatórias: MaaT Pharma(EURONEXT: MAAT – a “Empresa”), uma biotecnologia francesa de estágio clínico e pioneira no desenvolvimento de Terapias de Ecossistemas de MicrobiomaTM (MET) dedicada a melhorar os resultados de sobrevivência para pacientes com câncer, anuncia hoje o início da cobertura de suas ações pela Kepler Cheuvreux.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
ΛΥΩΝ, Γαλλία – (BUSINESS WIRE)–$MAAT- Ρυθμιστικά Νέα: MaaT Pharma(EURONEXT: MAAT – η «Εταιρεία»), μια γαλλική βιοτεχνολογία κλινικού σταδίου και πρωτοπόρος στην ανάπτυξη θεραπειών οικοσυστήματος μικροβιώματοςTM (MET) αφιερωμένο στη βελτίωση των αποτελεσμάτων επιβίωσης για ασθενείς με καρκίνο, today announces the initiation of coverage of its stock by Kepler Cheuvreux.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, Ranska – (BUSINESS WIRE) –$MAAT–Sääntelyuutiset: MaaT Pharma(EURONEXT: MAAT – "yritys"), ranskalainen kliinisen vaiheen biotekniikka ja edelläkävijä mikrobiomiekosysteemiterapioiden kehittämisessäTM (MET), joka on omistettu parantamaan syöpäpotilaiden eloonjäämistuloksia, today announces the initiation of coverage of its stock by Kepler Cheuvreux. With a research report named “The Microbiome revolution”, Kepler Cheuvreuxtoday initiates coverage of MaaT Pharma with a Buy recommendation.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LIONE, Francia–(BUSINESS WIRE)–$MAAT–Notizie normative: MaAT Pharma(EURONEXT: MAAT – la “Società”), una biotecnologia francese in fase clinica e pioniera nello sviluppo di terapie ecosistemiche del microbiomaTM (MET) dedicato a migliorare i risultati di sopravvivenza per i pazienti con cancro, annuncia oggi l'inizio della copertura del proprio titolo da parte di Kepler Cheuvreux.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, Frankrijk–(BUSINESS WIRE)–$MAAT–Regulerend nieuws: MaaT Pharma(EURONEXT: MAAT – het “Bedrijf”), een Franse biotech in de klinische fase en een pionier in de ontwikkeling van microbiome-ecosysteemtherapieënTM (MET) gewijd aan het verbeteren van overlevingsresultaten voor patiënten met kanker, kondigt vandaag de start aan van de dekking van zijn voorraad door Kepler Cheuvreux.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, France–(WIRE OWO)–$MAAT– Awọn iroyin ilana: MaaT Pharma(EURONEXT: MAAT - “Ile-iṣẹ”), imọ-ẹrọ imọ-ẹrọ ti ile-iwosan ti Faranse kan ati aṣáájú-ọnà kan ni idagbasoke ti Awọn Itọju Ẹjẹ Ecosystem MicrobiomeTM (MET) igbẹhin si imudarasi awọn abajade iwalaaye fun awọn alaisan ti o ni akàn, today announces the initiation of coverage of its stock by Kepler Cheuvreux.
MaaT Pharma Announces Initiation Of Coverage Of Its Stock By Kepler Cheuvreux
LYON, Francja–(BUSINESS WIRE)–$MAAT–Wiadomości prawne: MaaT Pharma(EURONEXT: MAAT – „Firma”), francuska biotechnologia na etapie klinicznym i pionier w rozwoju terapii mikrobiomowych ekosystemówTM (MET) zajmujący się poprawą wyników przeżycia pacjentów z chorobą nowotworową, ogłasza dziś rozpoczęcie pokrycia swoich akcji przez Kepler Cheuvreux. Z raportem badawczym o nazwie „Rewolucja mikrobiomu”, Kepler Cheuvreuxinicjuje dziś zasięg MaaT Pharma z rekomendacją Kupuj.
Affluent Medical : Mise en ouvre d'un contrat de liquidité avec Kepler Cheuvreux. | MarketScreener
Affluent Medical Affluent Medical : Mise en ouvre d'un contrat de liquidité avec Kepler Cheuvreux. 14-Juin-2021 / 08:30 CET/CEST Information réglementaire transmise par EQS Group. Le contenu de ce communiqué est de la responsabilité de l'émetteur.
Sartorius Stedim Biotech SA: Implementation of a new contract of liquidity with Kepler Cheuvreux
DJ Sartorius Stedim Biotech SA: Implementation of a new contract of liquidity with Kepler Cheuvreux Sartorius Stedim Biotech SA Sartorius Stedim Biotech SA: Implementation of a new contract of liquidity with Kepler Cheuvreux 04-May-2021 / 13:15 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Kepler
Contact Kepler, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack